Encompass Health’s SWOT analysis: stock navigates Medicare changes

Encompass Health reported 11% year-over-year EBITDA growth in Q3 2025 and ended the year with Q4 results above analyst expectations, while FY2026 guidance also topped Street estimates. The company generated $1.42B of EBITDA on $6.07B of revenue over the last 12 months through Q1 2026, with a 14-year dividend streak and nearly 12% dividend growth supporting the fundamental case. Key near-term catalysts include the expected FY2027 Medicare inpatient rehabilitation payment rule, with analysts looking for a 2.5% to 3.0% rate increase, though second-half 2025 volume softness remains a risk.

Analysis

EHC looks less like a pure “defensive healthcare” name and more like a levered beneficiary of a slow structural trade-down in post-acute care. If the Medicare update lands in the expected 2.5-3.0% range, the more important effect is not the headline rate but the signaling value: it validates IRF economics while pressuring lower-acuity settings whose reimbursement and staffing models are less resilient. That should widen the gap versus SNFs and hospital-based rehab programs, especially if hospital systems keep optimizing discharge pathways toward higher-outcome, lower-readmission sites.

The key second-order issue is that EHC’s valuation is being framed off earnings growth, but the real debate is occupancy durability. The stock can re-rate if management proves that the second-half volume softness was transitory; if not, the market will start discounting new beds as capacity risk rather than growth optionality. The next two quarters matter more than the next year: a clean volume inflection would likely pull forward multiple expansion, while another weak print would cap the upside even with favorable reimbursement.

The contrarian view is that consensus may be underestimating how much of the bull case is already “pre-paid” in the share price via expectations of benign policy and steady share gains. That makes the setup asymmetric: good policy plus stable volumes is not enough to drive a major rerating unless incremental admissions improve. Conversely, the downside is muted unless reimbursement surprises negatively or utilization rolls over more sharply, because the business still has operating leverage and a long dividend track record that should support investor demand on dips.

Key Decisions for Investors

• Long EHC into the Medicare IRF rule window (next 2-6 weeks) with a medium-term hold through the next 1-2 earnings prints; best risk/reward is a breakout only if same-store volumes re-accelerate, otherwise trim on a rate-driven pop.
• Pair trade: long EHC / short a basket of lower-acuity post-acute exposure such as SNF-heavy names and hospital rehab proxies over the next 3-6 months; thesis is reimbursement stability + share shift toward higher-acuity IRFs.
• Buy EHC call spreads or sell cash-secured puts into any post-rule volatility; structure for limited downside if the rate update is in-line, with upside tied to guidance revisions rather than the policy headline.
• Use a catalyst hedge: if EHC rallies >8-10% on the rule release without volume confirmation, fade part of the move via a short-dated call overwrite; the market may be overpricing one-time policy support versus organic demand.
• Avoid chasing on strength until management proves occupancy inflection; if the next quarter shows another soft same-store volume print, reduce exposure as the market will likely de-rate the new-bed growth narrative.